ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Roche Holding Ag

Roche Holding Ag (0QQ6)

229.20
0.00
(0.00%)
Cerrado 05 Enero 10:30AM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
229.20
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
651
0.00 Rango del Día 0.00
229.20 Rango de 52 semanas 229.20
Capitalización de Mercado [m]
Precio Anterior
229.20
Precio de Apertura
-
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
4,837
Acciones en circulación
0.00
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
0.00
Beneficio por acción (BPA)
-
turnover
58.72B
Beneficio neto
11.5B

Acerca de Roche Holding Ag

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Basel, Che
Fundado
-
Roche Holding Ag is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QQ6. The last closing price for Roche was CHF229.20. Over the last year, Roche shares have traded in a share price range of CHF 229.20 to CHF 229.20.

Roche currently has 0 shares in issue.

0QQ6 Últimas noticias

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease PADOVA study showed numerical delay in motor progression and...

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical labClinical...

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness Vabysmo PFS is the first and only prefilled syringe containing a bispecific...

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities The new cobas 6800/8800 systems 2.0 enhances throughput, run...

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma Long-term data confirm fixed-duration...

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash Basel, 9...

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma Exploratory long-term follow-up analysis of the phase III POLARIX...

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma Application is based on data from the...

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Acquisition supports Roche’s Pharma Strategy and...

Roche reports update on Phase III SKYSCRAPER-01 study results

Roche reports update on Phase III SKYSCRAPER-01 study results Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
100229.2229.2229.2937229.2DE
400229.2229.2229.25535229.2DE
1200229.2229.2229.24837229.2DE
2600229.2229.2229.24462229.2DE
5200229.2229.2229.25234229.2DE
15600229.2229.2229.26091229.2DE
26000229.2229.2229.24937229.2DE

0QQ6 - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Roche?
El precio actual de las acciones de Roche es CHF 229.20
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Roche?
Roche ha negociado en un rango de CHF 229.20 a CHF 229.20 durante el último año
¿Cuál es la moneda de reporte de Roche?
Roche presenta sus resultados financieros en CHF
¿Cuál es el último ingresos anual de Roche?
El último ingresos anual de Roche es CHF 58.72B
¿Cuál es el último beneficio anual de Roche?
El último beneficio anual de Roche es CHF 11.5B
¿Cuál es la dirección registrada de Roche?
La dirección registrada de Roche es GRENZACHERSTRASSE 124, BASEL, 4070
¿Cuál es la dirección del sitio web de Roche?
La dirección del sitio web de Roche es www.roche.com
¿En qué sector industrial opera Roche?
Roche opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M
m0n m0n 3 minutos hace
I was in TOYRF and it was halted in a
friday and resumed trading on the following
Monday. 

$TWOH buckle up 
TOYRF TWOH
microcapbiotech microcapbiotech 5 minutos hace
Sorry, I meant molasses going uphill in the winter.
MRKR
jimr1717 jimr1717 5 minutos hace
Tesla Crashes Into Oncoming Car, Saves the Life of a Pedestrian.

15 Oct 2024,


https://www.autoevolution.com/news/tesla-veers-to-avoid-pedestrian-who-fell-right-in-front-of-it-crashes-into-oncoming-car-241294.html
TSLA
StayHumble StayHumble 5 minutos hace
Markets Primed💹Must be 💹JUMBO SHORT💹 $SHMP ✅ $10!
SHMP
nelson1234 nelson1234 5 minutos hace
no problemo!!!
pos_stock_hoarder pos_stock_hoarder 6 minutos hace
B b b but at least they were woke and that's what it's all about. In the insane world of D's!
JV44 JV44 6 minutos hace
Huge sectors incompassing all factors of human life...tremendous potential worldwide...food sector has me intrigued...Go Breakthrough Chemistry products and team!...GLTUA
MGON
IB_ IB_ 7 minutos hace
Did you pocket profit ??????????

IB_🤴
SXOOF
fuagf fuagf 7 minutos hace
Hot head, i think, solved. Two days ago i went to get milk and on noticing the time was just after 10am thought, ok why not visit the pub for one or two. And watch some golf. The Sentry in Maui, 1st of the 2025 season in on. Some eight hours later i said to the manager, "I feel better today than i
copytele copytele 8 minutos hace
WELL CASH-IN A LITTLE $$$ , AND COME AND VISIT ME & MY FAMILY IN "ALASKA"~~~~~~BING MY NAME ; ANDY HEHNLIN ?
BTQQF
Lime Time Lime Time 8 minutos hace
Try Canada or discount vendor. Can't buy lower than .0001

I'm loading all these at .0001 for a pumpy new year.

Also OTC Rule Changes coming again 2025
PRCX
Huggy Bear Huggy Bear 8 minutos hace
Yeah, that a real stretch all right.
HMBL
demonsmith demonsmith 9 minutos hace
I think by wensday
TWOH
Truthfan Truthfan 9 minutos hace
“If CRL were so important for NWBO, why would kelly ganjei who is listed as co-inventor of the combo patent leave CRL for AmplifyBio along with his two high-caliber associates?”

All three personnel mentioned in your post are from Toucan Capital…..Ganjei, Yoon, and Khoury. I know you
NWBO
Hosai Hosai 9 minutos hace
Anavex post on wall street bets - https://www.reddit.com/r/wallstreetbets/comments/1htw4nu/avxl_alzheimers_stock_delivering_tendies/
AVXL
TheHound TheHound 9 minutos hace
IPIX is dead as well as its association w/ B and the laser boys as evidenced by its lack of reporting or communication with anyone.
IPIX
Konaploinks Konaploinks 9 minutos hace
The term “probably object framework” isn’t standard in quantum computing literature. However, if we interpret it as a framework designed to handle probabilistic objects or models, its integration with quantum computing, particularly in combinatorial optimization, presents both opportunities and chal
al44 al44 9 minutos hace
Wake up America, learn from England-

https://media.gettr.com/group6/getter/2025/01/05/15/8e6f6a6b-a0d9-4007-c30a-5e4b0e40c7f0/bc5970ddaa9d6164f55efe27c8a8210a_768x0.jpg
krab krab 9 minutos hace
At times you come out with the most unmeaningful remarks, that makes no sense !!!
FNMA
IB_ IB_ 10 minutos hace
You do not lower the price when you are selling all you are allowed to make !!!!!!!!!!!!!!!!!
That would be stupid ............

" If Adderall is getting more competitive, we may be lowering prices to maintain same market share which would decrease revs."

IB_
ELTP
3331 3331 10 minutos hace
GetSeriousOk Post #325074:
Friday, 12/22/2023 12:02:48 PM

Positives for BIEL:

1. It's a real company with a real product.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wr
BIEL
Zardiw Zardiw 11 minutos hace
#DDAmanda Video - $FCUV - Gain: +137% Video Analysis - #1 Stock Screener / Scanner

Questions/Support: 760 702-2009 - Hans@DDAmanda.com

https://www.youtube.com/watch?v=39M1FdrWh4g

Z
FCUV
sylvia07 sylvia07 11 minutos hace
I know naked shorts are in dbmm but I think it was the website it self I heard was fake, if shorts was not in it stock barber and other liars would not be working so hard to convince they are not.
DBMM
Value_Investor Value_Investor 12 minutos hace
Do you know where or from which brokerage firm I can buy PRCX shares now? I wish to Buy-Out the Entire float at $0.0001, instead of $0.000001!

Because buying its OTC peer (FCCN) at its Record-High $41.3 = buying PRCX at $0.3496 which is 3,496 Times of my desired price $0.0001!
PRCX

Su Consulta Reciente

Delayed Upgrade Clock